1. MJ Prior et al. A randomized, placebo-controlled trial of acetaminophen for treatment of migraine headache. Headache 2010; 50:819.

2. CC Suthisisang et al. Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine. Headache 2010; 50:808.

3. C Suthisisang et al. Efficacy of low-dose ibuprofen in acute migraine treatment: systematic review and meta-analysis. Ann Pharmacother 2007; 41:1782.

4. EA MacGregor. In the clinic. Migraine. Ann Intern Med 2013; 159:ITC5-1.

5. A sumatriptan needle-free injector for migraine. Med Lett Drugs Ther 2010; 52:50.

6. SD Silberstein. Migraine. Lancet 2004; 363:381.

7. A sumatriptan patch (Zecuity) for migraine. Med Lett Drugs Ther 2013; in press.

8. RB Lipton et al. Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled crossover study. Cephalalgia 2009; 29:826.

9. MM Johnston and AM Rapoport. Triptans for the management of migraine. Drugs 2010; 70:1505.

10. Zolmitriptan (Zomig) nasal spray for migraine. Med Lett Drugs Ther 2004; 46:7.

11. V Tullo et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine: a double-blind, randomized, multicenter, Italian study. Neurol Sci 2010; 31:S51.

12. G Roberto et al. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database. Cephalalgia 2013; Aug 6 (epub).

13. Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2013; 55:e44.

14. FDA Public Health Advisory. Combined use of 5-hydroxytryptamine receptor agonists (triptans), selective serotonin reuptake inhibitors (SSRIs) or selective serotonin/norepinephrine reuptake inhibitors (SNRIs) may result in life-threatening serotonin syndrome. 7/19/2006. Last updated August 16, 2013. Available at www.fda.gov. Accessed November 12, 2013.

15. MJ Láinez et al. Crossover, double-blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy. Eur J Neurol 2007; 14:269.

16. JR Saper and AN DaSilva. Medication overuse headache: history, features, prevention and management strategies. CNS Drugs 2013; 27:867.

17. SJ Tepper. Medication-overuse headache. Continuum (Minneap Minn) 2012; 18:807.

18. SD Silberstein et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012; 78:1337.

19. E Loder et al. The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache 2012; 52:930.

20. T Pringsheim et al. Acute treatment and prevention of menstrually related migraine headache: evidence-based review. Neurology 2008; 70:1555.

21. EA MacGregor et al. Safety and tolerability of frovatriptan in the acute treatment of migraine and prevention of menstrual migraine: results of a new analysis of data from five previously published studies. Gend Med 2010; 7:88.

22. V Limmroth and MC Michel. The prevention of migraine: a critical review with special emphasis on beta-adrenoceptor blockers. Br J Clin Pharmacol 2001; 52:237.

23. V Shaygannejad et al. Comparison of the effect of topiramate and sodium valporate in migraine prevention: a randomized blinded crossover study. Headache 2006; 46:642.

24. HC Diener et al. Topiramate in migraine prophylaxis–results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004; 251:943.

25. F Ashtari et al. Adouble-blind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxis. Acta Neurol Scand 2008; 118:301.

26. S Silberstein et al. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache 2009; 49:1153.

27. HC Diener et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2007; 27:814.

28. M Linde et al. Gabapentin or pregabalin for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev 2013; 6:CD010609.

29. DW Dodick et al. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther 2009; 31:542.

30. S Tarlaci. Escitalopram and venlafaxine for the prophylaxis of migraine headache without mood disorders. Clin Neuropharmacol 2009; 32:254.

31. Botulinum toxin for chronic migraine. Med Lett Drugs Ther 2011; 53:7.

32. BJ Gales et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines. Ann Pharmacother 2010; 44:360.

33. S Holland et al. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012; 78:1346.

34. RB Lipton et al. Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology 2004; 63:2240.

35. J Schoenen et al. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 1998; 50:466.

36. A Peikert et al. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia 1996; 16:257.

37. PS Sándor et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology 2005; 64:713.

38. HC Diener et al. Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention–a randomized, double-blind, multicentre, placebo-controlled study. Cephalalgia 2005; 25:1031.

39. ML Hilaire et al. Treatment of migraine headaches with sumatriptan in pregnancy. Ann Pharmacother 2004; 38:1726.

40. K Nezvalová-Henriksen et al. Triptan safety during pregnancy: a Norwegian population registry study. Eur J Epidemiol 2013; 28:759.

41. In brief: warning against use of valproate for migraine prevention during pregnancy. Med Lett Drugs Ther 2013; 55:45.